{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-136748","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2022-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.852643+00:00","generated_at":"2026-06-26T02:07:45.439018+00:00","sec_items":["5.02","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Magenta Therapeutics enters amended employment agreements with two executives","bullets":["Thomas Beetham (CLO) base salary $435,000, target incentive 40% of base, amended severance details.","David Nichols (CTO) base salary $362,000, target incentive 40% of base, amended severance details.","Severance: 0.75x base plus pro-rata target outside change in control; 1x base plus 100% target and accelerated vesting within change in control period.","Agreements effective May 2, 2022, supersede prior employment agreements.","Standard COBRA subsidies included; subject to release and noncompetition covenant."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-136748","json":"https://secwatch.observer/filing/0001193125-22-136748.json","markdown":"https://secwatch.observer/filing/0001193125-22-136748.md","text":"https://secwatch.observer/filing/0001193125-22-136748.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522136748/0001193125-22-136748-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312522136748/d337873d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T02:07:45.439018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}